Cargando…

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts

Detalles Bibliográficos
Autores principales:	Martín, Iván, Such, Esperanza, Navarro, Blanca, Villamón, Eva, Vicente, Ana, Mora, Elvira, Pedrola, Laia, Ibáñez, Mariam, López-Pavía, María, Tormo, Mar, Serrano, Alicia, Sanz, Miguel Ángel, Cervera, José, Sanz, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802591/ https://www.ncbi.nlm.nih.gov/pubmed/29235468 http://dx.doi.org/10.1038/s41408-017-0016-9

Ejemplares similares

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
por: Narang, Neha Chopra, et al.
Publicado: (2016)

Gaucher-like cells in myelodysplastic syndrome with ring sideroblasts
por: El Khoury, Christelle, et al.
Publicado: (2022)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)
por: Ohba, Rie, et al.
Publicado: (2012)

New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts()
por: Ribeiro, Lorena Bedotti, et al.
Publicado: (2016)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

Comment: In Response to “Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome”
por: Gajendra, Smeeta
Publicado: (2017)

Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia
por: Kjelland, Jacob D., et al.
Publicado: (2017)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
por: Divoux, Marion, et al.
Publicado: (2020)

When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms
por: Girard, Sandrine, et al.
Publicado: (2022)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts
por: Kang, Min-Gu, et al.
Publicado: (2015)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
por: Lazo-Langner, Alejandro, et al.
Publicado: (2019)

Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Kumar, Ashutosh, et al.
Publicado: (2018)

Marrow iron staining should always be performed to diagnose Myelodysplastic/myeloproliferative neoplasia with ring sideroblasts and thrombocythemia.
por: Chauffaille, Maria de Lourdes Lopes Ferrari, et al.
Publicado: (2019)

Refractory anemia with ring sideroblasts and thrombocytosis
por: Pradhan, Sarita
Publicado: (2017)

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome
por: Ochi, Tetsuro, et al.
Publicado: (2022)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis
por: Aoyama, Yumi, et al.
Publicado: (2019)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study
por: Donaires, Flávia Sacilotto, et al.
Publicado: (2016)

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia
por: Jekarl, Dong Wook, et al.
Publicado: (2010)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Refractory anemia with ring sideroblasts in a young individual
por: Cho, Jin-Hee, et al.
Publicado: (2010)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

P716: GENE EXPRESSION ANALYSIS REVEALS UNIQUE CHARACTERISTICS OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS
por: Chen, Wanshu, et al.
Publicado: (2023)

P1035: RING SIDEROBLASTS <15% WAS AN INDEPENDENT RISK FACTOR FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH SF3B1 MUTATION AND THROMBOCYTOSIS
por: LI, Fuhui, et al.
Publicado: (2023)

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia
por: Gómez-Seguí, Inés, et al.
Publicado: (2014)

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome
por: Clough, Courtnee A., et al.
Publicado: (2022)

Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
por: Adema, Vera, et al.
Publicado: (2022)

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
por: Tefferi, A, et al.
Publicado: (2016)

Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes
por: Patel, Jay L., et al.
Publicado: (2020)

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
por: Palomo, Laura, et al.
Publicado: (2019)

A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
por: Liquori, Alessandro, et al.
Publicado: (2021)

The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
por: Boultwood, Jacqueline, et al.
Publicado: (2008)

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
por: Visconte, Valeria, et al.
Publicado: (2014)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kdaceajog2fpdt1d5f08h091hs